Anticoagulant low molecular weight heparin has the advantages of exact anticoagulant effect, strong antithrombotic effect, less adverse reactions and high bioavailability. In recent years, under the influence of the accelerated aging process of the population and the continuous increase in the incidence of chronic diseases, more than 15 million people worldwide die of thromboembolic diseases every year. Thrombotic disease is a serious threat to human life and health. Low molecular weight heparin is a key drug for the prevention and treatment of this disease, and its market size is continuously expanding. Therefore, low-molecular-weight heparin has become the most important anticoagulant drug in clinical practice, accounting for more than 85%. At present, low-molecular-weight heparin anticoagulants mainly include enoxaparin sodium injection, nadroparin calcium injection, dalteparin sodium injection, and bemiparin sodium injection. Among them, enoxaparin sodium injection accounts for a large proportion of the global market, and the global sales of original research Sanofi have stabilized in recent years, with an annual average of more than 1.5 billion US dollars.
Low-molecular-weight heparin is an upgraded product of unfractionated heparin, and its clinical therapeutic effect is better. It is gradually replacing unfractionated heparin as the mainstream anticoagulant drug for the treatment of thrombosis, pulmonary embolism and myocardial infarction, and has broad market development prospects. At the same time, a large number of clinical trials on low molecular weight heparin are being carried out gradually, and its application space will continue to expand in the future.
We Sinoway can supply you this kind of products with high quality and competitive price.
IPv6 network supported
English
中文
français
Deutsch
русский
español
português
العربية
日本語
한국의
Türkçe
